Is 68Ga-DOTA-NOC PET/CT indicated in patients with clinical, biochemical or radiological suspicion of neuroendocrine tumour?

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 8, 2012, Pages 1278-1283

  Ambrosini, Valentina ^a   Campana, Davide ^a   Nanni, Cristina ^a   Nanni, Silvia Cambioli ^a   Tomassetti, Paola ^a   Rubello, Domenico ^b   Fanti, Stefano ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Ospedale S Maria della Misericordia   (Italy)

Author keywords

68Ga DOTA NOC; Appropriate use; NET; PET CT

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GALLIUM 68; SOMATOSTATIN RECEPTOR 4; TETRAXETAN; 68GA DOTANOC; 68GA-DOTANOC; DIAGNOSTIC AGENT; ORGANOMETALLIC COMPOUND;

ARTICLE; BIOCHEMICAL COMPOSITION; CANCER PATIENT; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; FALSE NEGATIVE RESULT; FOLLOW UP; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; METABOLISM; PATHOLOGY; SCINTISCANNING;

HUMANS; NEUROENDOCRINE TUMORS; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RETROSPECTIVE STUDIES;

EID: 84865453781     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2146-4     Document Type: Article

References (36)

1. Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current status of gastrointestinal carcinoids. Gastroenterology 2005;128:1717-51. (Pubitemid 40692562)
2. Taal BG, Visser O. Epidemiology of neuroendocrine tumours. Neuroendocrinology 2004;80 Suppl 1:3-7. (Pubitemid 39382359)
3. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-72.
4. Adams S, Baum R, Rink T, Schumm-Dräger PM, Usadel KH, Hör G. Limited value offluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 1998;25:79-83. (Pubitemid 28107907)
5. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48:508-18. (Pubitemid 47571404)
6. Kowalski J, Henze M, Schuhmacher J, Mäcke HR, Hofmann M, Haberkorn U. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 2003;5:42-8. (Pubitemid 36596544)
7. Ambrosini V, Campana D, Bodei L, Nanni C, Castellucci P, Allegri V, et al. 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med 2010;51:669-73.
8. Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging 2011;38:2125-35.
9. Carrió I. Nuclear medicine, scientific publishing and the era of cost containment. Eur J Nucl Med Mol Imaging 2011;38:2111-3.
10. Rockall AG, Reznek RH. Imaging of neuroendocrine tumours (CT/MR/US). Best Pract Res Clin Endocrinol Metab 2007;21:43-68.
11. Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, et al. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging 2010;37:2004-10.
12. Zhernosekov KP, Filosofov DV, Baum RP, Aschoff P, Bihl H, Razbash AA, et al. Processing of generator-produced 68Ga for medical application. J Nucl Med 2007;48:1741-8. (Pubitemid 47572722)
13. Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schäfer M, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007;34:1617-26. (Pubitemid 47476920)
14. Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M. Chromogranin A-biological function and clinical utility in neuroendocrine tumor disease. Ann Surg Oncol 2010;17:2427-43.
15. Peracchi M, Gebbia C, Basilisco G, Quatrini M, Tarantino C, Vescarelli C, et al. Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids. Eur J Endocrinol 2005;152:443-8. (Pubitemid 40439498)
16. Spadaro A, Ajello A, Morace C, Zirilli A, D'arrigo G, Luigiano C, et al. Serum chromogranin-A in hepatocellular carcinoma: diagnostic utility and limits. World J Gastroenterol 2005;11:1987-90. (Pubitemid 40520997)
17. Malaguarnera M, Cristaldi E, Cammalleri L, Colonna V, Lipari H, Capici A, et al. Elevated chromogranin A (CgA) serum levels in the patients with advanced pancreatic cancer. Arch Gerontol Geriatr 2009;48:213-7.
18. Sciola V, Massironi S, Conte D, Caprioli F, Ferrero S, Ciafardini C, et al. Plasma chromogranin a in patients with inflammatory bowel disease. Inflamm Bowel Dis 2009;15:867-71.
19. Larsen AI, Helle KB, Christensen M, Kvaløy JT, Aarsland T, Dickstein K. Effect of exercise training on chromogranin A and relationship to N-ANP and inflammatory cytokines in patients with chronic heart failure. Int J Cardiol 2008;127:117-20. (Pubitemid 351707511)
20. O'Connor DT, Pandlan MR, Carlton E, Cervenka JH, Hslao RJ. Rapid radioimmunoassay of circulating chromogranin A: in vitro stability, exploration of the neuroendocrine character of neoplasia, and assessment of the effects of organ failure. Clin Chem 1989;35:1631-7. (Pubitemid 19212423)
21. Hsiao RJ, Mezger MS, O'Connor DT. Chromogranin A in uremia: progressive retention ofimmunoreactive fragments. Kidney Int 1990;37:955-64. (Pubitemid 20089229)
22. Hoshino K, Suzuki J, Yamauchi K, Inoue H. Psychological stress evaluation of patients with bronchial asthma based on the chromogranin a level in saliva. J Asthma 2008;45:596-9.
23. Capellino S, Lowin T, Angele P, Falk W, Grifka J, Straub RH. Increased chromogranin A levels indicate sympathetic hyperactivity in patients with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol 2008;35:91-9.
24. Giusti M, Sidoti M, Augeri C, Rabitti C, Minuto F. Effect of shortterm treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man. Eur J Endocrinol 2004;150:299-303. (Pubitemid 38443779)
25. Gulubova M, Vlaykova T. Chromogranin A-, serotonin-, synaptophysin-and vascular endothelial growth factor-positive endocrine cells and the prognosis of colorectal cancer: an immunohistochemical and ultrastructural study. J Gastroenterol Hepatol 2008;23:1574-85.
26. Angelsen A, Syversen U, Haugen OA, Stridsberg M, Mjølnerød OK, Waldum HL. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings? Prostate 1997;30:1-6. (Pubitemid 27053534)
27. Giovanella L, Marelli M, Ceriani L, Giardina G, Garancini S, Colombo L. Evaluation of chromogranin A expression in serum and tissues of breast cancer patients. Int J Biol Markers 2001;16:268-72. (Pubitemid 34168387)
28. Campana D, Nori F, Piscitelli L, Morselli-Labate AM, Pezzilli R, Corinaldesi R, et al. Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol 2007;25:1967-73. (Pubitemid 46972778)
29. Bajetta E, Ferrari L, Martinetti A, Celio L, Procopio G, Artale S, et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer 1999;86:858-65. (Pubitemid 29399927)
30. Nobels FR, Kwekkeboom DJ, Coopmans W, Schoenmakers CH, Lindemans J, De Herder WW, et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuronspecific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 1997;82:2622-8. (Pubitemid 27337883)
31. Molina R, Alvarez E, Aniel-Quiroga A, Borque M, Candás B, Leon A, et al. Evaluation of chromogranin A determined by three different procedures in patients with benign diseases, neuroendocrine tumors and other malignancies. Tumour Biol 2011;32:13-22.
32. Ambrosini V, Nanni C, Zompatori M, Campana D, Tomassetti P, Castellucci P, et al. (68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2010;37:722-7.
33. Putzer D, Gabriel M, Henninger B, Kendler D, Uprimny C, Dobrozemsky G, et al. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3- octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med 2009;50:1214-21.
34. Castellucci P, Pou Ucha J, Fuccio C, Rubello D, Ambrosini V, Montini GC, et al. Incidence ofincreased 68Ga-DOTANOC uptake in the pancreatic head in a large series of extrapancreatic NET patients studied with sequential PET/CT. J Nucl Med 2011;52:886-90.
35. Al-Ibraheem A, Bundschuh RA, Notni J, Buck A, Winter A, Wester HJ, et al. Focal uptake of 68Ga-DOTATOC in the pancreas: pathological or physiological correlate in patients with neuroendocrine tumours? Eur J Nucl Med Mol Imaging 2011;38:2005-13.
36. Wild D, Christ E, Caplin ME, Kurzawinski TR, Forrer F, Brändle M, et al. Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. J Nucl Med 2011;52:1073-8.